Given the intense efforts, both past and current, in the development of novel inhibitors of tryptophan dioxygenases for research and for use in cancer therapy, we suggest that the inhibitors described in this report will provide excellent tools to elucidate the individual roles and interactions between IDO1 and TDO2 in driving cancer-mediated immune suppression. Here, TDO2 is linked to cancer.